Maarten de Jong
Directeur/Membre du Conseil chez TigaTx, Inc.
Profil
Maarten de Jong joined EQT Partners in October 2023 as a Partner dedicated to the Healthcare sector, based in London.
Prior to joining EQT Partners, Maarten was a partner at Moelis & Company in New York, where he led the expansion of its global healthcare platform and was part of the Management Committee.
A chemist by training, De Jong has nearly three decades of experience advising healthcare companies on M&A and capital markets transactions.
Previously Maarten worked at MeesPierson, Lehman Brothers and Barclays, where he most recently was their Global Head of Life Sciences.
Maarten holds an MSc in Chemistry from the University of Utrech.
Postes actifs de Maarten de Jong
| Sociétés | Poste | Début |
|---|---|---|
TigaTx, Inc.
 TigaTx, Inc. BiotechnologyHealth Technology TigaTx, Inc. is a biotechnology company that focuses on developing first-in-class, engineered IGA as neutrophil engagers to fight cancer. The company is based in Boston, MA. TigaTx is backed by excellent investors and has an accomplished scientific advisory board. It was founded by Jeanette Leusen and the CEO is Anne Altmeyer. | Directeur/Membre du Conseil | - |
| EQT Partners UK Advisors LLP | Private Equity Investor | 01/10/2023 |
Anciens postes connus de Maarten de Jong
| Sociétés | Poste | Fin |
|---|---|---|
| MOELIS & COMPANY | Corporate Officer/Principal | 01/10/2023 |
Barclays Capital, Inc.
 Barclays Capital, Inc. Investment Banks/BrokersFinance Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team. | Corporate Officer/Principal | 01/08/2014 |
Lehman Brothers, Inc.
 Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | Corporate Officer/Principal | 01/09/2008 |
Formation de Maarten de Jong
| University of Utrecht | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MOELIS & COMPANY | Finance |
| Entreprise privées | 4 |
|---|---|
Lehman Brothers, Inc.
Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | Finance |
Barclays Capital, Inc.
Barclays Capital, Inc. Investment Banks/BrokersFinance Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team. | Finance |
| EQT Partners UK Advisors LLP | Finance |
TigaTx, Inc.
TigaTx, Inc. BiotechnologyHealth Technology TigaTx, Inc. is a biotechnology company that focuses on developing first-in-class, engineered IGA as neutrophil engagers to fight cancer. The company is based in Boston, MA. TigaTx is backed by excellent investors and has an accomplished scientific advisory board. It was founded by Jeanette Leusen and the CEO is Anne Altmeyer. | Health Technology |